Subject:
- Active Sustance: Upadacitinib
- Name: Rinvoq®
- Therapeutic area: Axial spondyloarthritis
- Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG
Time table:
- Start: 01.09.2022
- Publication of assessment: 01.12.2022
- End of public hearing: 22.12.2022
- Final decision by G-BA: middle of February 2023
Comparative therapy:
- A TNF-α inhibitor (etanercept or adalimumab or golimumab or certolizumab pegol)